Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability.

Molecular cancer therapeutics - 1 Jul 2010

Degenhardt Yan, Greshock Joel, Laquerre Sylvie, Gilmartin Aidan G, Jing Junping, Richter Mark, Zhang Xiping, Bleam Maureen, Halsey Wendy, Hughes Ashley, Moy Christopher, Liu-Sullivan Nancy, Powers Scott, Bachman Kurtis, Jackson Jeffrey, Weber Barbara, Wooster Richard

Abstract excerpt

Polo-like kinases are a family of serine threonine kinases that are critical regulators of cell cycle progression and DNA damage response. Predictive biomarkers for the Plk1-selective inhibitor GSK461364A were identified by comparing the genomics and genetics of a panel of human cancer cell lines with their response to a drug washout followed by an outgrowth assay. In this assay, cell lines that have lost p53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomal Instability
Share to Cyclin-Dependent Kinase Inhibitor p21

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoblotting

Share to Inhibitory Concentration 50

Share to Mitosis

Share to Polo-Like Kinase 1

Share to Polyploidy

Share to Thiophenes

Source

Identifiers

PMID: 20571075
DOI: 10.1158/1535-7163.MCT-10-0095

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability.PMID 20571075Read ↗

The CINs of Polo-Like Kinase 1 in CancerSemantic proximity Read ↗

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read ↗

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in OncologySemantic proximity Read ↗

Sensitivity of TP53-Mutated Cancer Cells to the Phytoestrogen Genistein Is Associated With Direct Inhibition of Plk1 Activity.Semantic proximity Read ↗

Enabling and Disabling Polo-like Kinase 1 Inhibition through Chemical GeneticsSemantic proximity Read ↗

Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapySemantic proximity Read ↗

Targeting Polo-like Kinase in Cancer TherapySemantic proximity Read ↗

Small Interfering RNA–Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth in AnimalsSemantic proximity Read ↗

PLK-1 Targeted Inhibitors and Their Potential against TumorigenesisSemantic proximity Read ↗

The Role of Polo-like Kinase 1 in Carcinogenesis: Cause or Consequence?Semantic proximity Read ↗

Plk1 Inhibition Causes Post-Mitotic DNA Damage and Senescence in a Range of Human Tumor Cell LinesSemantic proximity Read ↗

Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.